Future studies should investigate the broader physiological impact of RCC1 inhibition, identify potential toxicities in normal tissues, and develop tumor-specific targeting strategies such as nanoparticle-based delivery or selective small-molecule inhibitors to minimize off-target effects. Here, RCC1 is linked to neoplasm.